EUVIMEDEUVIMED entdecken
Multizentrische Studie

QuantiFERON‐CMV Monitoring Post‐Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes

Beatrice Z Sim iD, Chhay Lim, Siobhan Mineely, Joe Sasadeusz, Lynette Chee, Jason Trubiano, Andrew Grigg, Jen Kok, Surekha Tennakoon, Violet Z Zhu, Tim Spelman, David Ritchie und 2 weitere

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70152 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Beatrice Z Sim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus. Die Arbeit nennt 32 Literaturangaben. Gefördert von: NHMRC Centre for Research Excellence, National Health and Medical Research Council, MSD Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune responses may determine natural history and optimal management of cytomegalovirus (CMV) reactivation following allogeneic hematopoietic cell transplantation (alloHCT). To assess this, we performed serial QuantiFERON‐CMV (QFCMV, Qiagen) and QuantiFERON‐Monitor (QF‐monitor, Qiagen) tests, measuring CMV‐specific T cell interferon‐γ responses (IFNγ), and stimulators of innate (TLR7) and adaptive immunity (CD3), respectively.

Methods

In a prospective multicenter study of adult CMV‐seropositive alloHCT recipients, QFCMV and QF‐monitor tests were collected serially. Association with CMV outcomes was analyzed using multivariable Cox and mixed effects regression analysis.

Results

Overall, 119 patients had 385 QFCMV tests (median [IQR]:3 [3–4] per patient). csCMVi occurred in 45.4% patients. QFCMV reactivity was achieved in 16% of patients at 6 weeks, 38.3% at 12 weeks, and 40.2% any time during the study. Reactivity was predictive of lower peak CMV viral load in the 6 weeks following testing (−0.41 × log 10 [95% CI −0.77 to −0. 04 × log 10 ], p = 0.02), but did not impact csCMVi. Analysis of mitogen‐stimulated IFNγ responses within QFCMV testing showed reduced risk of csCMVi in the following 6 weeks (adjusted HR 0.92 [95% CI 0.85–0.99], p = 0.025) and each 1 IU/mL IFNγ increase was associated with decreased peak viral load (−0.02 × log 10 [95% CI −0.03 to 0.00 × log 10 ], p = 0.02). QF‐monitor was not associated with any CMV outcomes.

Conclusion

QFCMV reactivity was associated with lower peak CMV viral load but not csCMVi. Mitogen‐stimulated IFNγ response correlated with csCMVi, suggesting a role for broader assessment of cellular immunity post‐transplant. Despite incorporating adaptive immunity measures, QF‐monitor was limited in assessing CMV risk. QFCMV reactivity was infrequently achieved in the early post‐allogeneic stem cell transplant period. Qualitative QFCMV result was associated with peak CMV viral load but not clinically significant infection, while magnitude of the mitogen response predicted reduction in clinically significant CMV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsCytomegalovirusHumansMaleFemaleMiddle AgedAdultProspective StudiesViral LoadInterferon-gammaTransplantation, HomologousVirus ActivationAgedAdaptive ImmunityInterferon-gamma Release Tests

Stichwörter der Autor:innen

allogeneic stem cell transplantcellular immunitycytomegalovirusimmune monitoringstem cell transplantation

Substanzen

Interferon-gamma

Autor:innen und Institutionen

  • Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Department of Infectious Diseases, Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, Australia.

ORCID-Profile: Beatrice Z Sim

Förderung

  • NHMRC Centre for Research Excellence
  • National Health and Medical Research Council
  • MSD Australia

Zitieren

APA

Sim, B. Z., Lim, C., Mineely, S., Sasadeusz, J., Chee, L., Trubiano, J., Grigg, A., Kok, J., Tennakoon, S., Zhu, V. Z., Spelman, T., Ritchie, D., Slavin, M. A., & Yong, M. K. (2025). QuantiFERON‐CMV Monitoring Post‐Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes. Transplant Infectious Disease. https://doi.org/10.1111/tid.70152

Vancouver

Sim BZ, Lim C, Mineely S, Sasadeusz J, Chee L, Trubiano J, et al. QuantiFERON‐CMV Monitoring Post‐Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes. Transplant Infectious Disease. 2025. doi:10.1111/tid.70152

BibTeX
@article{Sim2025,
  author = {Sim, Beatrice Z and Lim, Chhay and Mineely, Siobhan and Sasadeusz, Joe and Chee, Lynette and Trubiano, Jason and Grigg, Andrew and Kok, Jen and Tennakoon, Surekha and Zhu, Violet Z and Spelman, Tim and Ritchie, David and Slavin, Monica A and Yong, Michelle K},
  title = {QuantiFERON‐CMV Monitoring Post‐Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70152}
}
Kostenlos starten →